OncoPharm

Highlights from ASCO's 2022 annual meeting.

Maya Leiva, PharmD, BCOP joins the Pod for Pride to give an overview of cancer screenings in the transgender population.

Looking at some interesting articles as possible predictors of what to expect next in NSCLC and AML. NADIM: https://pubmed.ncbi.nlm.nih.gov/?term=35576508 Ven + Intensive Chemo: https://doi.org/10.1016/S2352-3026(22)00100-4

By listener request, we discuss how to utilize our favorite guidelines.

Dive into the world of docetaxel, a vital chemotherapy drug in cancer treatment. Learn how it works, its side effects, and the science behind its pharmacokinetics. Discover FDA-approved uses and the importance of proper dosing to optimize patient care. This enlightening discussion sheds light on how to administer chemotherapy safely and effectively.

The Landmarks of OncoPharm series returns to discuss 2 landmark studies (and 1 editorial) in head & neck cancer. Editorial: https://ascopubs.org/doi/pdf/10.1200/JCO.22.00274 EUORTC Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Intergroup Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032646

Dive into the fascinating world of melanoma, exploring its different forms like cutaneous and uveal. Discover the significance of treatment strategies, including surgical resection and immune checkpoint inhibitors. Learn about melanoma's unique patterns of metastasis and the crucial role of the immune system. Don't forget the importance of regular screenings in early detection and management!

Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550). The AGILE study. If you can't say anything nice. Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).

Explore the hidden dangers of combining ribociclib with tamoxifen, particularly the risks of QT prolongation. Uncover insights from the MONALEESA-7 study that emphasize the importance of awareness for healthcare professionals. This cautionary tale sheds light on potential drug interactions and the crucial need for patient safety in cancer treatment.

Catching on recent FDA approvals on relatlimab/nivolumab (it's relatLimab not relatimab) as well as Lu-PSMA-177 based on the VISION trial.